ExoXpert and Neucore Bio Collaborate to Optimize Exosome Loading

• ExoXpert, a CDMO specialising in exosome production, has entered into a strategic partnership with Neucore Bio to optimise exosome loading.

• The collaboration aims to maximise the therapeutic effect of Neucore’s Fibroblast EV Engineering (FiXE) discovery platform.

ExoXpert, a Contract Development and Manufacturing Organisation (CDMO) specialising in exosome production, has announced a strategic partnership with Neucore Bio, a company at the forefront of non-viral engineered delivery technology. The partnership will utilise ExoXpert’s platform to evaluate advanced exosome loading.

Under the agreement, ExoXpert will use its ExoPulse platform to test and optimise the efficient loading of proprietary payloads into exosomes. This is part of Neucore’s Fibroblast EV Engineering (FiXE) discovery platform. ExoPulse is ExoXpert’s latest exosome-based therapeutic platform, currently used in clinical trials, and has been specifically designed to facilitate the production and loading of exosomes.

The aim of this partnership is to provide greater clarity on how to maximise the therapeutic effect of Neucore’s FiXE platform as it advances clinical development.

Kenneth Morand, PhD, CEO of Neucore Bio, commented on the collaboration, “This collaboration is an important step in the loading validation and application of our FiXE platform using advanced, non-viral exosomes for therapeutic delivery. We believe ExoXpert’s demonstrated exosome experience with its ExoPulse platform will enable a highly efficient and collaborative process to answer this critical question in our scientific strategy.”

Hugues Wallemacq, CEO of ExoXpert and EXO Biologics, also expressed his views on the partnership, “EXO Biologics recently created ExoXpert as an exosome CDMO to meet the demand for specialised GMP grade exosome manufacturing services internationally. As a therapeutic exosome developer, this was something EXO Biologics needed, but we also realised the international market needed this as well. ExoXpert has started working with a significant number of international cell and gene therapy developers that need a combination of exosome manufacturing and knowledge to develop new products for the benefit of patients. Partnering with Neucore will enable ExoXpert to further extend ExoXpert’s expertise in loading exosomes to Neucore’s FiXE platform.”